A Canadian researcher has won a 2025 Breakthrough Prize in Life Sciences for discovering the GLP-1 hormone used in diabetes ...

President Donald Trump's administration has decided not to cover expensive, high-demand obesity treatments under the ...

Semaglutide improved maximum walking distance in patients with type 2 diabetes and symptomatic peripheral artery disease.

While gastrointestinal issues are the most common side effects, a recent study by the University of British Columbia linked ...

The eyes also might help detect seniors at risk for a common syndrome in which they emerge from surgery in a state of ...

The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent ...

Results from the SUMMIT trial suggest that tirzepatide is as effective in preventing heart failure events in those with ...

Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...

An estimated 15 million Americans are currently taking semaglutide weight loss drugs, which are proven to impact alcohol ...

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

According to BMO Capital Markets, Rybelsus’ outcomes in SOUL were “inconsistent,” failing to significantly lower ...

Medical professionals point out that functional impairment in individuals with PAD is often overlooked in its early stages ...